Elevated expression levels of the solute carrier family 5 member 2 (SLC5A2) gene, which is targeted by sodium–glucose co-transporter 2 (SGLT2) inhibitors, in the tibial artery and the potassium inwardly rectifying channel subfamily J member 11 (KCNJ11) gene, which is targeted by sulfonylureas, in the blood were linked to an increased risk of any ischemic stroke (AIS) (KCNJ11: odds ratio (OR) = 1.11, 95% confidence interval (CI) = 1.01–1.21; p = 0.033; SLC5A2: OR = 1.05, 95% CI = 1.01–1.10; p = 0.017, respectively), according to the SMR analysis. This evidence concerns the gene SLC5A2 and androgen insensitivity syndrome.